



Proteomics International
LABORATORIES LTD

ASX Release

22 July 2026

ASX code: PIQ

Proteomics International signs national distribution agreement with Healius for Promarker® portfolio

Highlights

- National distribution agreement executed with Healius Limited (ASX: HLS) as the exclusive pathology distribution partner for the Promarker® portfolio in Australia.
- Initial term of three years, with an option to extend for a further three years by mutual agreement.
- Proteomics International will continue to perform all testing through its accredited laboratory infrastructure and provide clinical reporting.
- Provides access to Healius' national pathology network, including more than 2,000 patient collection centres and established referrer relationships.
- Establishes the Company's first national distribution partnership for commercial implementation of the Promarker® portfolio across Australia.
- Implementation activities will commence immediately, with phased commercial rollout planned during FY27.
- Investors are invited to attend a webinar on Thursday, 23 July 2026 from 11am AEST where CEO and Managing Director, David Morris will cover the agreement in more detail.

Agreement Overview

Proteomics International Laboratories Ltd (ASX: PIQ) ("Proteomics International" or "the Company") is pleased to announce that it has entered into a national Australian distribution agreement with Healius Limited (ASX: HLS) ("Healius"), appointing Healius as the exclusive pathology distribution partner for the Promarker® portfolio and establishing the Company's first national commercial distribution partnership.

Under the agreement, Healius has been appointed the exclusive Australian pathology distribution partner for the Company's Promarker® portfolio of predictive and diagnostic blood tests for an initial term of three years, with an option to extend the agreement for a further three years by mutual agreement.

Proteomics International will continue to perform all testing through its accredited laboratory infrastructure and provide clinical reporting, while Healius will utilise its pathology distribution infrastructure to support specimen collection, pathology distribution and market access across Australia.

The agreement provides Proteomics International with access to Healius' collection centre network, comprising more than 2,000 patient collection centres and established relationships with general practitioners, specialists, hospitals and other healthcare providers throughout Australia.

Proteomics International will retain responsibility for the Promarker® portfolio, including laboratory testing, clinical reporting, scientific and medical support, quality and regulatory compliance. Healius will be responsible for pathology distribution through its national infrastructure, including specimen collection, referrer engagement, market access activities and support for the Promarker® portfolio.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

The parties will work collaboratively on implementation and commercial rollout activities, with each organisation continuing to focus on its respective areas of expertise.

The agreement represents the first national commercial distribution partnership secured for the Promarker® portfolio and establishes a national distribution pathway for commercial implementation across Australia. It is intended to support national access to the Promarker® portfolio through existing pathology collection and distribution infrastructure without requiring Proteomics International to establish its own national specimen collection network.

As the Promarker® portfolio is at an early stage of commercialisation, the revenue that may be generated under the distribution agreement cannot be reliably estimated at this time. The Company will update the market on material developments in accordance with its continuous disclosure obligations.

The commercial terms of the agreement are confidential.

Commercial Significance

The agreement establishes the Company's preferred Australian commercialisation model for the Promarker® portfolio. Proteomics International will retain responsibility for laboratory testing, scientific support, quality systems and clinical reporting, while leveraging Healius' established pathology distribution infrastructure and referrer relationships. The Company believes this model supports capital-efficient market access and commercial implementation of the Promarker® portfolio.

Commentary

Proteomics International Chief Executive Officer and Managing Director, David Morris, said:

"This agreement provides a national distribution pathway for the Promarker® portfolio and represents an important step in our commercialisation strategy. By partnering with Healius, we can leverage an established pathology network while maintaining responsibility for laboratory testing, reporting and clinical support."

"By combining Proteomics International's accredited laboratory capability with Healius' pathology distribution infrastructure, we have established a scalable pathway to support the phased rollout of the Promarker® portfolio across Australia."

"We look forward to working closely with Healius to support clinician awareness and adoption activities for the Promarker® portfolio."

Healium Group Executive Customer and Commercial, Anthea Muir, said:

"We are pleased to partner with Proteomics International to provide clinicians and patients with access to the Promarker® portfolio through Healium's pathology network."

"The Promarker® portfolio complements Healium's pathology offering by expanding the range of predictive and diagnostic testing available to Australian clinicians."

Next Steps

The parties will immediately commence implementation activities, including operational integration, information technology integration, laboratory workflow implementation, clinician education and engagement, market access planning and commercial launch preparation.

Implementation will occur in a phased manner, with commercial rollout expected to commence progressively during FY27 following completion of implementation activities.

Investor Webinar

Investors are invited to join a webinar where CEO and Managing Director, David Morris will discuss today's announcement in more detail, followed by an interactive Q+A session.

Date: Thursday, 23 July, 2026

Time: 11:00am AEST / 9:00am AWST

Register: To register your interest in the event, please visit the following link:

https://us02web.zoom.us/webinar/register/WN_MZwybxPQO-JCKOi6Oq7_Q

After registering, investors will receive a confirmation email with information about joining the webinar. Participants will be invited to submit questions to be covered after the formal presentation.

Promarker® Portfolio

Promarker®D – Diabetic Kidney Disease

Promarker®D is a predictive blood test designed to identify people with type 2 diabetes who are at increased risk of developing chronic kidney disease before conventional clinical indicators become apparent, supporting earlier clinical intervention and more personalised patient management.

Promarker®Eso – Oesophageal Cancer Risk Assessment

Promarker®Eso is a blood test designed to assist in identifying patients with chronic gastro-oesophageal reflux disease and Barrett's oesophagus who may be at increased risk of developing oesophageal cancer, supporting earlier investigation and informed clinical decision-making.

Promarker®Endo – Endometriosis

Promarker®Endo is a diagnostic blood test designed to assist clinicians in the diagnosis of endometriosis and support earlier identification of the condition.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

-ENDS-

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr James Williams
Chairman
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Mr David Morris
CEO & Managing Director
Proteomics International Laboratories Ltd
+61 8 9389 1992
E: enquiries@proteomicsinternational.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Forward Looking Statements

Commercial outcomes arising from this agreement will depend on a range of factors, including implementation timing, clinician adoption, patient utilisation, reimbursement pathways, regulatory approvals where applicable, and prevailing market conditions.

This announcement contains forward-looking statements regarding future events and the future performance of Proteomics International. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These forward-looking statements are based on information available to the Company as at the date of this announcement and should not be relied upon as guarantees of future performance. Except as required by law, the Company undertakes no obligation to update any forward-looking statements.